Why Xeris Biopharma Holdings (XERS) Has Investors Paying Attention Again

Why Xeris Biopharma is back on investors’ radar

Xeris Biopharma Holdings (XERS) recently presented new clinical data on Gvoke, Recorlev and its XP-8121 hypothyroidism candidate to endocrinologists at three major medical meetings this fall.

Recent buyers have leaned into the newsflow. Xeris Biopharma’s share price has a 30-day return of 26.35% and a year-to-date share price return of 40.27%. The 3-year total shareholder return is about 5x, which some investors may view as momentum aligned with renewed confidence in its endocrinology pipeline and product portfolio.

Spot emerging endocrinology opportunities by scanning our hand-picked 33 healthcare AI stocks, which, like Xeris Biopharma Holdings, are working at the intersection of clinical data and targeted therapies.

After a 30-day jump of 26.35% and a 3-year total return near 5x, Xeris Biopharma now forces a timing question. Is it more logical to commit at today’s price, or to wait for a reset before the next leg of the thesis is priced in?

Most Popular Narrative: 16% Undervalued

Xeris Biopharma Holdings last closed at $10.31, while the most followed narrative assigns a fair value of $12.29 that frames the recent rally as only a partial repricing of its endocrinology story.

The impending launch of XP-8121, which utilizes proprietary delivery technology to address a significant unmet need in hypothyroidism, opens the door to a high-value market segment underserved by innovation, with the potential to drive new revenue streams and long-term margin expansion.

See why 10 investors see Xeris Biopharma Holdings as 16% undervalued.

Result: Fair Value of $12.29 (UNDERVALUED)

Still, the Xeris Biopharma story leans heavily on a few products, so any setback in XP-8121 trials or Recorlev adoption could quickly challenge this fair value narrative.

Find out about the key risks to this Xeris Biopharma Holdings narrative.

Next Steps

The mix of upside potential and clear risks around Xeris Biopharma can feel polarising, so consider moving quickly and weighing the trade off yourself by reviewing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Xeris Biopharma?

If Xeris Biopharma has sharpened your focus on focused opportunities, do not stop here. Broaden your watchlist with a few targeted searches that could surface your next high conviction idea.

• Target potential mispricings in quality companies by running the 33 high quality undervalued stocks to filter for strong fundamentals at compressed valuations.
• Prioritise resilience and capital preservation by scanning the 32 resilient stocks with low risk scores to tilt toward businesses with steadier risk profiles.
• Uncover lesser-known opportunities before broader attention arrives by using the 20 high quality undiscovered gems to focus on under-followed stocks with solid financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com